| 25 |
Wu SG, Li FY, Chen Y, et al. Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis [J]. J Cancer Res Clin Oncol, 2017, 143(3): 467-474.
|
| 26 |
Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival [J]. Ann Surg Oncol, 2013, 20(9): 2828-2834.
|
| 27 |
Hou L, Qiu M, Chen M, et al. The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database [J]. Gland Surg, 2021, 10(6): 1889-1898.
|
| 28 |
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J]. CA Cancer J Clin, 2017, 67(2): 93-99.
|
| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 2 |
Zheng A, Guo BL, Zhang JG, et al. Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002) [J]. Chin Med J (Engl), 2021, 134(13): 1569-1575.
|
| 3 |
Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022 [J]. CA Cancer J Clin, 2022, 72(5): 409-436.
|
| 4 |
Soran A, Dogan L, Isik A, et al. The effect of primary surgery in patients with De Novo Stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study [J]. Ann Surg Oncol, 2021, 28(9): 5048-5057.
|
| 5 |
莫雪莉, 董洁, 韩冬. 不同阶段HER2阳性乳腺癌分层治疗的要点解析 [J/OL]. 中华临床医师杂志(电子版), 2020, 14(11): 862-865.
URL
|
| 6 |
Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 [J]. J Natl Compr Canc Netw, 2023, 21(6): 594-608.
|
| 7 |
de Maar JS, Luyendijk M, Suelmann BBM, et al. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018 [J]. Breast Cancer Res Treat, 2023, 198(2): 253-264.
|
| 8 |
Wang R, Zhu Y, Liu X, et al. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer [J]. BMC Cancer, 2019, 19(1): 1091.
|
| 9 |
Rao X, Chen Y, Beyrer J, et al. Clinical and genomic characteristics of patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor [J]. Clin Cancer Res, 2023, 29(17): 3372-3383.
|
| 10 |
Lambertini M, Ferreira AR, Di Meglio A, et al. Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: A multicenter retrospective cohort study [J]. Clin Breast Cancer, 2017, 17(8): 601-610.e2.
|
| 11 |
Wang J, Liu Y, Liang Y, et al. Clinicopathologic features, genomic profiles and outcomes of younger vs older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients [J]. Front Oncol, 2023, 13: 1152575.
|
| 12 |
Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States [J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(6): 809-815.
|
| 13 |
Gera R, Chehade HELH, Wazir U, et al. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis [J]. Sci Rep, 2020, 10(1): 2952.
|
| 14 |
Zhu S. Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer [J]. Breast J, 2022, 2022: 5049445.
|
| 15 |
Asaad M, Yonkus JA, Hoskin TL, et al. Primary tumor resection in patients with stage IV breast cancer: 10-year experience [J]. Breast J, 2021, 27(12): 863-871.
|
| 16 |
Li Y, Wang S, Yang W, et al. Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer: A SEER-based study [J]. Medicine, 2021, 100(27): e26619.
|
| 17 |
Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01 [J]. Ann Surg Oncol, 2018, 25(11): 3141-3149.
|
| 18 |
ULAŞ KAHYA B, SüTCüOĞLU O, YAZıCı O, et al. Early local therapy for the primary site in De Novo stage IV breast cancer: results of a randomized clinical trial (EA2108) [J]. J Clin Oncol, 2022, 40(33): 3898.
|
| 19 |
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial [J]. Lancet Oncol, 2015, 16(13): 1380-1388.
|
| 20 |
King TA, Lyman JP, Gonen M, et al. Prognostic impact of 21-Gene recurrence score in patients with stage IV breast cancer: TBCRC 013 [J]. J Clin Oncol, 2016, 34(20): 2359-2365.
|
| 21 |
Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial [J]. Ann Surg, 2019, 269(6): 1163-1169.
|
| 22 |
Bjelic-Radisic V, Fitzal F, Knauer M, et al. Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial [J]. BMC Cancer, 2020, 20(1): 392.
|
| 23 |
Lane WO, Thomas SM, Blitzblau RC, et al. Surgical resection of the primary tumor in women with De Novo Stage IV breast cancer: contemporary practice patterns and survival analysis [J]. Ann Surg, 2019, 269(3): 537-544.
|
| 24 |
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J]. Ann Oncol, 2020, 31(12): 1623-1649.
|